Enhanced Effectivity of an ALK5-Inhibitor after Cell-Specific Delivery to Hepatic Stellate Cells in Mice with Liver Injury

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  van Beuge, Marike Marjolijn ^a,c   Prakash, Jai ^a,d   Lacombe, Marie ^b   Post, Eduard ^a   Reker Smit, Catharina ^a   Beljaars, Leonie ^a   Poelstra, Klaas ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Kreatech Diagnostics   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3 (PYRIDIN 2 YL) 4 (4 QUINONYL) 1H PYRAZOLE; CELL MARKER; DESMIN; HUMAN SERUM ALBUMIN; LY 364947; MANNOSE 6 PHOSPHATE; PYRAZOLE DERIVATIVE; SOMATOMEDIN B RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG STRUCTURE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; MALE; MOUSE; NONHUMAN; RAT; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STELLATE CELL; UPREGULATION;

ANIMALS; COLLAGEN; DISEASE MODELS, ANIMAL; HEPATIC STELLATE CELLS; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS; MALE; MICE; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRROLES; RATS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA;

EID: 84874166297     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056442     Document Type: Article

References (30)

1. Lee U, Friedman S, (2011) Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 25 (2) (): 195-206.
2. Derynck R, Zhang YE, (2003) Smad-dependent and smad-independent pathways in TGF-ß family signaling. Nature 425: 577-584.
3. Zhang YE, (2009) Non-smad pathways in TGF-beta signaling. Cell Res 19 (1) (): 128-139.
4. de Gouville AC, Huet S, (2006) Inhibition of ALK5 as a new approach to treat liver fibrotic diseases. Drug News Perspect 19 (2) (): 85-90.
5. de Gouville AC, Boullay V, Krysa G, Pilot J, Brusq JM, et al. (2005) Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol 145 (2) (): 166-177.
6. Arribillaga L, Dotor J, Basagoiti M, Riezu-Boj J, Borrs-Cuesta F, et al. (2011) Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosis. Cytokine 53 (3) (): 327-333.
7. Prud'homme GJ, (2007) Pathobiology of transforming growth factor ß in cancer, fibrosis and immunologic disease, and therapeutic considerations. Laboratory Investigation 87: 1077-1091.
8. Beljaars L, Molema G, Weert B, Bonnema H, Olinga P, et al. (1999) Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 29 (5) (): 1486-1493.
9. Gressner AM, Weiskirchen R, (2006) Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 10 (1) (): 76-99.
10. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S, (2002) Roles of TGF-beta in hepatic fibrosis. Front Biosci 7: 793-807.
11. Gressner OA, Gressner AM, (2008) Connective tissue growth factor: A fibrogenic master switch in fibrotic liver diseases. Liver Int 28 (8) (): 1065-1079.
12. de Bleser P, Jannes P, van Buul-Offers SC, Hoogerbrugge CM, van Schravendijk CFH, et al. (1995) Insulinlike growth factor-II/Mannose 6-phosphate receptor is expressed on CCl4-exposed rat fat-storing cells and facilitates activation of latent transfroming growth factor-ß in cocultures with sinusoidal endothelial cells. Hepatology 21: 1429-1437.
13. Greupink R, Bakker HI, van Goor H, de Borst MH, Beljaars L, et al. (2006) Mannose-6-phosphate/insulin-like growth factor-II receptors may represent a target for the selective delivery of mycophenolic acid to fibrogenic cells. Pharm Res 23 (8) (): 1827-1834.
14. Ghosh P, Dahms NM, Kornfeld S, (2003) Mannose 6-phosphate receptors: New twists in the tale. Nat Rev Mol Cell Biol 4: 202-212.
15. Prakash J, de Borst MH, van Loenen-Weemaes AM, Lacombe M, Opdam F, et al. (2008) Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis. Pharm Res 25 (10) (): 2427-2439.
16. Beljaars L, Olinga P, Molema G, de Bleser P, Geerts A, et al. (2001) Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P28-HSA). Liver 21: 320-328.
17. Geerts A, Niki T, Hellemans K, De Craemer D, Van Den Berg K, et al. (1998) Purification of rat hepatic stellate cells by side scatter-activated cell sorting. Hepatology 27 (2) (): 590-598.
18. Hageman J, Eggen B, Rozema T, Damman K, Kampinga H, et al. (2005) Radiation and transforming growth factor-beta cooperate in transcriptional activation of the profibrotic plasminogen activator inhibitor-1 gene. Clinical Cancer Research 11: 5956-5964.
19. Jonk LJ, Itoh S, Heldin CH, ten Dijke P, Kruijer W, (1998) Identification and functional characterization of a smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. Journal of Biological Chemistry 273: 21145-21152.
20. Pinzani M, (2005) Fibrosis in chronic liver diseases: Diagnosis and management. J Hepatol 42 (Suppl 1) (1): 22-36.
21. Lahn M, Kloeker S, Berry B, (2005) TGF-beta inhibitors for the treatment of cancer. Expert Opin Investig Drugs 14 (6) (): 629-643.
22. van Beuge MM, Prakash J, Lacombe M, Post E, Reker-Smit C, et al. (2011) Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the rho-kinase inhibitor Y27632. Pharm Res (8) pp. 2045-2054.
23. Sedlaczek N, Jia JD, Bauer M, Herbst H, Ruehl M, et al. (2001) Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. Am J Pathol 158 (4) (): 1239-1244.
24. Fu K, Corbley M, Sun L, Friedman J, Shan F, et al. (2008) SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler Thromb Vasc Biol 28 (4) (): 665-671.
25. Higashiyama H, Yoshimoto D, Kaise T, Matsubara S, Fujiwara M, et al. (2007) Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp Mol Pathol 83 (1) (): 39-46.
26. Dooley S, Weng H, Mertens P, (2009) Hypotheses on the role of transforming growth factor-beta in the onset and progression of hepatocellular carcinoma. Digestive Diseases 27 (2) (): 93-101.
27. Ling L, Lee WC, (2011) TGF-beta type I receptor (Alk5) kinase inhibitors in oncology. Curr Pharm Biotechnol 12: 2202.
28. Anderton M, Mellor H, Bell A, Sadler C, Pass M, et al. (2011) Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol 39 (6) (): 916-924.
29. Laping N, Everitt J, Frazier K, Burgert M, Portis M, et al. (2007) Tumor-specific efficacy of transforming growth factor-beta RI inhibition in eker rats. Clin Cancer Res 13 (10) (): 3087-3099.
30. Sherman M, (2010) Hepatocellular carcinoma: New and emerging risks. Dig Liver Dis 42 (Suppl 3):: S215-S222.